Phibro Animal Health (NASDAQ:PAHC) Raised to Overweight at JPMorgan Chase & Co.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was upgraded by JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating in a note issued to investors on Monday, Marketbeat Ratings reports. The firm presently has a $35.00 target price on the stock, up from their previous target price of $25.00. JPMorgan Chase & Co.'s price objective points to a potential upside of 16.86% from the stock's current price.

A number of other equities analysts have also issued reports on the company. Wall Street Zen raised Phibro Animal Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Morgan Stanley set a $26.00 price target on Phibro Animal Health and gave the stock an "equal weight" rating in a research note on Wednesday, June 25th. BNP Paribas upgraded shares of Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. Finally, BNP Paribas Exane upgraded shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target for the company in a research report on Monday, June 16th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $24.40.

Phibro Animal Health Stock Performance

Shares of Phibro Animal Health stock traded up $0.05 on Monday, reaching $29.95. 121,153 shares of the company were exchanged, compared to its average volume of 215,183. The company has a debt-to-equity ratio of 2.67, a quick ratio of 1.23 and a current ratio of 2.91. The company's 50-day moving average is $23.83 and its two-hundred day moving average is $22.19. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of 38.78, a P/E/G ratio of 0.47 and a beta of 0.75. Phibro Animal Health has a 1-year low of $16.16 and a 1-year high of $30.59.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.52 by $0.11. The business had revenue of $347.80 million for the quarter, compared to analysts' expectations of $352.41 million. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. As a group, research analysts expect that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phibro Animal Health

Institutional investors and hedge funds have recently modified their holdings of the business. Nuveen LLC bought a new stake in shares of Phibro Animal Health during the 1st quarter worth about $10,312,000. Invesco Ltd. lifted its holdings in Phibro Animal Health by 92.3% in the 1st quarter. Invesco Ltd. now owns 387,739 shares of the company's stock worth $8,282,000 after purchasing an additional 186,087 shares during the last quarter. Axecap Investments LLC acquired a new stake in Phibro Animal Health in the 1st quarter worth approximately $3,696,000. Millennium Management LLC lifted its holdings in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company's stock worth $7,733,000 after purchasing an additional 154,281 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Phibro Animal Health by 56.7% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 301,173 shares of the company's stock worth $6,325,000 after purchasing an additional 108,918 shares during the last quarter. Institutional investors and hedge funds own 99.34% of the company's stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.